TY  - CONF 
AU  - Baraliakos, X.
AU  - Coates, L. C.
AU  - Gossec, L.
AU  - Jeka, S.
AU  - MERA VARELA, ANTONIO JOSE
AU  - Schulz, B.
AU  - Rissler, M.
AU  - Das Gupta, A.
AU  - Perella, C.
AU  - Pournara, E.
PY  - 2019
SN  - 0003-4967
UR  - http://hdl.handle.net/20.500.11940/15517
AB  - Background Secukinumab (SEC) has provided significant and sustained improvement in the signs and symptoms of active psoriatic arthritis (PsA) and ankylosing spondylitis 1. Evidence on the efficacy of biologics in the treatment of PsA patients (pts)...
TI  - SECUKINUMAB improves axial manifestations in patients with psoriatic arthritis and inadequate response to NSAIDS: primary analysis of the maximise trial
DO  - 10.1136/annrheumdis-2019-eular.2932
KW  - CHUS
VL  - 78
ER  -